Many researchers consider obesity mainly as an unfavorable balance between a high energy intake and low energy expenditure due to poor diet and inadequate exercise habits. However, overweight early in life is a risk factor for overweight LDK378 manufacturer and obesity later in life, and paradoxically underweight is another risk factor due to a “catch up” phenomenon. Obviously there exists some sort

of programming regarding weight development, at least in the earliest stages of life. Recent research has suggested that environmental contaminants could play an important role in modulating the balance between energy intake and expenditure, reviewed in (Janesick and Blumberg, 2011). In a study on mice it was found that prenatal exposure to tributyl tin (TBT) caused obesity later in life and the term “obesogens” was coined (Grun and Blumberg, 2006). This observation supports the hypothesis of fetal programming in humans as a source of certain disorders, such as obesity and diabetes, emerging many years later PD-0332991 mw (Barker et al., 2002). In addition to fetal programming, exposure to certain chemicals in adulthood is also important. Adult rats given persistent organic pollutants (POPs) via crude salmon oil become obese (Ruzzin et al., 2010), and pharmaceuticals, such as the antidiabetic drug rosiglitazone

(ROSI) acting on the important receptor peroxisome proliferator-activated receptor-gamma (PPAR-γ) increase body fat when administered to adult humans (Choi et al., 2010). Moreover, it was recently shown that thiazide antihypertensive agents induce visceral obesity when given to adult hypertensive patients (Eriksson et al., 2008). Taken together, these data indicates that exposure to chemicals not only in utero or early childhood could be of importance for the development of obesity. Bisphenol A (BPA) was discovered to be an artificial estrogen 3-mercaptopyruvate sulfurtransferase as early as the 1930s (Dodds, 1936), but the synthesis of another chemical, diethylstilbestrol (DES), with more

potent estrogenic properties precluded the use of BPA as a pharmaceutical agent. Today its main applications are as a hardener in plastic goods and as a monomer for production of polycarbonate plastics. As such, it is a high-volume chemical and circulating levels of this compound were measureable in about 98% of all subjects in a study of Swedish elderly persons (Olsen et al., 2012) confirming the National Health and Nutrition Examination Survey (NHANES) 2007–2008 where the urinary concentrations were measurable in 94% of the subjects (